The efficacy and cardiac toxicity of different‐dose pegylated liposomal doxorubicin in elderly patients with diffuse large B lymphoma
Cancer Medicine · 2023-02 · 12 (4) · 4184-4194
DOI: 10.1002/cam4.5280 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 06.10.2022. Verfasst von Li Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
In order to explore the impact of pegylated liposomal doxorubicin (PLD) dose intensity on survival outcomes of newly diagnosed elderly patients with diffuse large B‐cell lymphoma (DLBCL), we performed a retrospective study to compare the efficacy and adverse effects of RCEOP (70 mg/m 2 ), RCdOP (20–30 mg/m 2 ) and RCDOP (30–45 mg/m 2 ). The optimal PLD dose of patients with different clinical characteristics of subgroups was explored to provide a clue for the selection of clinical PLD dose.
Methods
A total of 335 DLBCL patients (60–85 years old) who were newly diagnosed and completed at least four cycles of RCE(D)OP were selected. The patients were mainly divided into RCEOP (126 cases) (epirubicin 70 mg/m 2 ), RCdOP (151 cases) (PLD 20–30 mg/m 2 ) and RCdOP (58 cases) (PLD 30–45 mg/m 2 ). The effects of different doses of PLD on clinical efficacy, cardiotoxicity and prognosis of patients were retrospectively analyzed. Subgroup analysis was performed to compare the clinical characteristics of different subgroups.
Results
Our study showed that PLD and epirubicin had similar efficacy (overall survival (OS) p = 0.776; progression‐free survival (PFS) p = 0.959). RCDOP (30–45 mg/m 2 PLD) group had a higher complete remission (CR) rate of 75.9% compared with RCdOP (20–30 mg/m 2 PLD) group (P D vs. d = 0.018). In the overall population, there was no significant difference in survival between RCDOP and RCdOP groups (OS P D vs. d = 0.661; PFS P D vs. d = 0.212). In patients with underlying cardiovascular diseases, the PFS of the RCDOP group was significantly better than the RCdOP group ( p = 0.043). Meanwhile, patients in the RCDOP group tended to have a better prognosis than those in the RCEOP group (OS: RCDOP vs. RCEOP p = 0.054, PFS: RCDOP vs. RCEOP p = 0.053). There was no significant difference in the incidence of cardiotoxicity and other adverse events among the three groups. For the low‐risk (age‐adjusted‐International Prognostic Index = 0/1) old patients without cardiovascular disease, RCdOP was considered a better strategy in OS ( p = 0.020).
Conclusion
In the general population, the CR rate in the RCDOP group was significantly higher than that in the RCdOP group ( p = 0.018). For elderly DLBCL patients with cardiovascular disease, the effect benefit brought by the PLD dose was more obvious, and the PFS of the RCDOP group was significantly better than that of the RCdOP group ( p = 0.043). Full dose of PLD is an efficient alternative in the treatment of patients with preexisting cardiovascular diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
- Program in Clinical Medicine, School of Medicine of Zhejiang University, Hangzhou, Zhejiang, China.
ORCID-Profile: Jianai Sun, Lulu Wang, Lixia Zhu, Xiujin Ye
Zitieren
APA
Li, L., Chen, R., Zhou, Sun, J., Wang, L., Zhu, L., Shen, H., Xie, W., & Ye, X. (2023). The efficacy and cardiac toxicity of different‐dose pegylated liposomal doxorubicin in elderly patients with diffuse large B lymphoma. Cancer Medicine, 12(4), 4184-4194. https://doi.org/10.1002/cam4.5280
Vancouver
Li L, Chen R, Zhou, Sun J, Wang L, Zhu L, et al. The efficacy and cardiac toxicity of different‐dose pegylated liposomal doxorubicin in elderly patients with diffuse large B lymphoma. Cancer Medicine. 2023;12(4):4184-4194. doi:10.1002/cam4.5280
BibTeX
@article{Li2023,
author = {Li, Li and Chen, Rongrong and Zhou, De and Sun, Jianai and Wang, Lulu and Zhu, Lixia and Shen, Huafei and Xie, Wanzhuo and Ye, Xiujin},
title = {The efficacy and cardiac toxicity of different‐dose pegylated liposomal doxorubicin in elderly patients with diffuse large B lymphoma},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {4},
pages = {4184--4194},
doi = {10.1002/cam4.5280}
}
EUVIMED